Search

everythinglearnresearchcommunity

for

Search:↓

Genetically at-risk healthy people show similar immune issues as those with Pemphigus vulgaris or Alopecia areata.

Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.

IL-17-producing γδ T cells help improve bone healing.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Autophagy helps control skin inflammation and cancer responses and regulates hair growth by affecting stem cell activity.

Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.

Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.

The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Alitretinoin may help treat alopecia areata.

Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.

A patient's grey hair regained color during treatment with adalimumab.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

The L412F variant of TLR3 is linked to skin infections, more viral infections, and autoimmune issues.

AIRE protein, defective in APECED patients, is found in skin and hair cells and interacts with cytokeratin 17.

Sparse hairless patches can develop and stabilize in alopecia areata under certain conditions.

Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.

TSC2-/meth cells can cause skin lesions, hair growth, and lung issues, and may be treated with chromatin remodeling agents.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

DP cells interact with immune cells, possibly causing hair loss in Alopecia Areata.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Damage to skin releases dsRNA, which activates TLR3 and helps in skin and hair follicle regeneration.

Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.

Inactive stem cells in hair follicles and muscles can avoid detection by the immune system.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Higher CRHR1 levels in AA patients lead to increased inflammation.

Alopecia areata causes unpredictable hair loss and requires personalized treatment.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.